pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2011-0-6-111-115pulmo-427Research ArticleОБЗОРЫREVIEWДлительно действующие β2-агонисты в терапии бронхообструктивных заболеваний легкихLong-acting β2-agonists in treatment of obstructive lung diseasesНенашеваН. М.NenashevaN. M.

д.м.н., проф. кафедры клинической аллергологии 

123242, Москва, ул. Баррикадная, 2/1. Тел.: (499)196-19-54.

ГБОУ ДПО "Российская медицинская академия последипломного образования" Минздравсоцразвития РоссииRussian Federation20112812201106111115Copyright © Ненашева Н.М., 20112011Ненашева Н.М.Nenasheva N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/427

Длительно действующие β2-агонисты в терапии бронхообструктивных заболеваний легких.

Long-acting β2-agonists in treatment of obstructive lung diseases.

бронхиальная астмахроническая обструктивная болезнь легкихбронхолитическая терапияформотеролbronchial asthmachronic obstructive pulmonary diseasebronchodilating therapyformoterolReferencesAnderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci.1993; 52 (26): 2145–2160.Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci.1993; 52 (26): 2145–2160.Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir. Med. 2001; 95 (Suppl. B): S7–S11.Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir. Med. 2001; 95 (Suppl. B): S7–S11.GINA, 2010. http://www.ginasthma.comGINA, 2010. http://www.ginasthma.comMitchell C., Jenkins C, Scicchitano R, Rubinfeld A. Adding formoterol is more effective and safer than doubling the dose of inhaled steroids in moderately severe asthma. Am. J. Respir. Crit. Care Med. 2000; 161: A197 (abstr.).Mitchell C., Jenkins C, Scicchitano R, Rubinfeld A. Adding formoterol is more effective and safer than doubling the dose of inhaled steroids in moderately severe asthma. Am. J. Respir. Crit. Care Med. 2000; 161: A197 (abstr.).Black J.L., Oliver B.G.G., Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists. Chest 2009; 136: 1095–1100.Black J.L., Oliver B.G.G., Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists. Chest 2009; 136: 1095–1100.Grainge C, Lau L., Ward J. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364: 2006–2015.Grainge C, Lau L., Ward J. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364: 2006–2015.Chowdhury B.A., Dal Pan G. The FDA and safe use of longacting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010; 362: 1169–1171.Chowdhury B.A., Dal Pan G. The FDA and safe use of longacting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010; 362: 1169–1171.GOLD, 2010. http://www.goldcopd.comGOLD, 2010. http://www.goldcopd.comSears M.R. Long-acting bronchodilators in COPD. Chest 2008; 133: 1057–1058.Sears M.R. Long-acting bronchodilators in COPD. Chest 2008; 133: 1057–1058.Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: A systematic review. Chest 2008; 133: 1079–1087.Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: A systematic review. Chest 2008; 133: 1079–1087.Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Res. Med. 2008; 102: 1701–1707.Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Res. Med. 2008; 102: 1701–1707.Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Res. Med. 1998; 92 (Suppl. A): 23–31.Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Res. Med. 1998; 92 (Suppl. A): 23–31.Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343–351.Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343–351.Busse W.W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionat in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 1999; 104: 1215–1222.Busse W.W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionat in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 1999; 104: 1215–1222.Цой А.Н. Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата / формотерола: слагаемые успеха. Consilium Medicum 2008; прил. "Болезни органов дыхания": 39–45.Цой А.Н. Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата / формотерола: слагаемые успеха. Consilium Medicum 2008; прил. "Болезни органов дыхания": 39–45.Bousquet J., Huchon G., Leclerc V. et al. A randomized double-blind, double-dummy, single-dose efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 6–12.Bousquet J., Huchon G., Leclerc V. et al. A randomized double-blind, double-dummy, single-dose efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 6–12.Мещерякова Н.Н., Белевский А.С. Атмосфера. Пульмонол. и аллергол. 2007; 4: 32–35.Мещерякова Н.Н., Белевский А.С. Атмосфера. Пульмонол. и аллергол. 2007; 4: 32–35.De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP / Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148.De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP / Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148.

The authors declare that there are no conflicts of interest present.